Health Technology

Trans Genic Inc.

Business Summary

Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.

Financial Highlights

Mar 2023	JPY	USD
Revenue	11,429.68M	84.34M
Gross Profit	1,994.83M	14.72M
Operating income	-25.15M	-0.18M
Income before tax	-331.80M	-2.44M
Net income	-409.66M	-3.02M
EBITDA	158.36M	1.16M
Diluted EPS	-24.32	-0.17
Dividends Per Share	5	0.03
Total Assets	10,672.93M	80.19M
Total liabilities	4,550.41M	34.19M
Total equity	6,018.04M	45.21M
Operating cash flow	-1,430.03M	-10.55M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Revenue	8,674.50M	11,046.67M	11,046.13M	12,576.56M	11,429.68M
Gross Profit	1,498.44M	1,779.72M	2,777.10M	3,835.96M	1,994.83M
Operating income	270.06M	62.70M	895.64M	1,837.30M	-25.15M
Income before tax	202.87M	-249.65M	695.20M	2,767.58M	-331.80M
Net income	202.21M	-440.71M	546.28M	1,876.33M	-409.66M
EBITDA	460.51M	292.68M	1,147.11M	2,065.26M	158.36M
Diluted EPS	11.90	-25.37	31.45	109.31	-24.32
Dividends Per Share	0	0	3	6	5
Total Assets	6,475.27M	7,571.68M	8,928.90M	10,441.20M	10,672.93M
Total liabilities	1,588.53M	3,154.97M	3,892.00M	3,804.41M	4,550.41M
Total equity	4,886.74M	4,416.61M	4,916.45M	6,532.77M	6,018.04M
Operating cash flow	147.69M	-20.98M	1,222.36M	1,789.20M	-1,430.03M

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Revenue	78.22M	101.60M	104.15M	111.91M	84.34M
Gross Profit	13.51M	16.36M	26.18M	34.13M	14.72M
Operating income	2.43M	0.57M	8.44M	16.35M	-0.18M
Income before tax	1.82M	-2.29M	6.55M	24.62M	-2.44M
Net income	1.82M	-4.05M	5.15M	16.69M	-3.02M
EBITDA	4.15M	2.69M	10.81M	18.37M	1.16M
Diluted EPS	0.10	-0.23	0.29	0.97	-0.17
Dividends Per Share	0	0	0.02	0.05	0.03
Total Assets	58.50M	70.13M	80.80M	86.02M	80.19M
Total liabilities	14.35M	29.22M	35.22M	31.34M	34.19M
Total equity	44.15M	40.91M	44.49M	53.82M	45.21M
Operating cash flow	1.33M	-0.19M	11.52M	15.92M	-10.55M

Valuation Measures

Mar 2023
PER	--
ROA	-3.88%
ROE	-6.52%
Operating margin	-0.22%
Profit margin	-3.58%

Key executives

Director, Manager-Finance & Accounting: Kazuo Watanabe
Director & Chief Technology Officer: Kenichi Yamamura
Director, Manager-Personnel & General Affairs: Yutaka Funabashi
Director & GM-Contract Research Organization: Shunichi Kitajima

Shareholders

FUJII MASAKI (1.0%)
Mutoh Co., Ltd. (0.9%)
Limousine International KK (0.8%)
Trans Genic Inc. (0.8%)
HARADA IKUO (0.8%)
FUKUNAGA KENJI /TRANS GENIC/ (0.8%)
YAMAZAKI MANABU /ZAMA/ (0.7%)
MIZUKOSHI ATSUSHI (0.6%)
Dimensional Fund Advisors LP (0.5%)
ISOBE GENSHIRO (0.5%)

Contact Details

Website:http://www.transgenic.co.jp
Address: ibb Fukuoka, 2/F, 2-3-36 Tenjin, Fukuoka, 810-0001, Japan
Phone: +81.92.288.8470

Related Companies

MASC Co. Ltd.
Trans Genic Restricted Stock Compensation Plan
LunaPath LLC
Kizuki Corporation
Galax Corp.
Medicinal Chemistry Pharmaceutical Co. Ltd.
TG Business Service Inc.
New Drug Research Center Inc.
GP Biosciences Ltd. /Genetic Analysis Business/
HOPE Co., Ltd.
Primmune Inc

Competitors

Last Updated on 9 Jun, 2023